Infectious disease

Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
Thursday, July 22, 2021

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.

Key Points: 
  • HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.
  • The companys management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 5, 2021.
  • Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease.
  • Coupled with Chembios extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease.

Children’s National Hospital and NIAID launch large study on long-term impacts of COVID-19 and MIS-C on kids

Retrieved on: 
Tuesday, July 20, 2021

, chief of the Division of Pediatric Infectious Diseases at Childrens National and lead researcher for this study.

Key Points: 
  • , chief of the Division of Pediatric Infectious Diseases at Childrens National and lead researcher for this study.
  • Participants who enroll more than 12 weeks after acute infection will attend study visits every six months for three years.
  • Of patients with MIS-C, 52% were critically ill.
    Study sites include Childrens National Hospital inpatient and outpatient clinics in the Washington, D.C. area, and the NIH Clinical Center in Bethesda, Maryland.
  • You will then be contacted by a study team member to review the study details and determine whether you are eligible to participate.

RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx

Retrieved on: 
Tuesday, July 20, 2021

"Momentum with Talicia is growing strongly and the addition of unrestricted Commercial coverage for Talicia by OptumRx, a major operator in U.S. healthcare coverage serving more than 26 million Americans, is an important advance in extending patient access to Talicia, which now extends to greater than 8 out of 10 covered U.S. Commercial lives," said Rick Scruggs, RedHill's Chief Commercial Officer.

Key Points: 
  • "Momentum with Talicia is growing strongly and the addition of unrestricted Commercial coverage for Talicia by OptumRx, a major operator in U.S. healthcare coverage serving more than 26 million Americans, is an important advance in extending patient access to Talicia, which now extends to greater than 8 out of 10 covered U.S. Commercial lives," said Rick Scruggs, RedHill's Chief Commercial Officer.
  • In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults.
  • Minimal to zero resistance to rifabutin, a key component of Talicia, was detected in RedHill's pivotal Phase 3 study.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

Michael R. Scoma is recognized by Continental Who's Who

Retrieved on: 
Thursday, July 1, 2021

MINEOLA, N.Y., July 1, 2021 /PRNewswire/ -- Michael R. Scoma is being recognized by Continental Who's Who as a Top Infectious Disease Specialist for his years of dedicated work in the field.

Key Points: 
  • MINEOLA, N.Y., July 1, 2021 /PRNewswire/ -- Michael R. Scoma is being recognized by Continental Who's Who as a Top Infectious Disease Specialist for his years of dedicated work in the field.
  • With over seventeen years of experience, Dr. Scoma is well versed in Infectious Disease treatment and care.
  • As an infectious disease specialist at NYU Langone Hospital in Long Island and his practice Scoma Medical Group PLLC, Dr. Scoma treats all patients with care and compassion.
  • As the founder of Scoma Medical Group PLLC, Dr. Scoma currently practices at 173 Mineola Boulevard, Suite 401A.

David R. Weber, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, June 25, 2021

A fellowship-trained infectious disease specialist, Dr. David R. Weber has garnered over 30 years of professional excellence in the medical field.

Key Points: 
  • A fellowship-trained infectious disease specialist, Dr. David R. Weber has garnered over 30 years of professional excellence in the medical field.
  • He is currently serving the medical community and patients at the University of Pittsburgh Medical Center Shadyside & the University of Pittsburgh Medical Center McKeesport.
  • With a commitment to excellence, Dr. Weber is board-certified in infectious disease and internal medicine by the American Board of Internal Medicine.
  • As a testament to his professional excellence, Dr. Weber was voted among the 2012 Best Doctors by Pittsburgh Magazine.

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021

Retrieved on: 
Monday, June 14, 2021

SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress taking place virtually from June 23-26, 2021.

Key Points: 
  • SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress taking place virtually from June 23-26, 2021.
  • Vir will hold a conference call and webcast on Friday, June 25, 2021, at 11:00 AM ET, to discuss the new data presented at EASL.
  • Vir Biotechnologyis a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Infectious Diseases Society of America Foundation, Johnson & Johnson Innovation - JLABS to Host 2021 IDea Incubator Competition

Retrieved on: 
Thursday, June 10, 2021

ARLINGTON, Va., June 10, 2021 /PRNewswire-PRWeb/ -- The Infectious Diseases Society of America (IDSA) Foundation, in collaboration with Johnson & Johnson Innovation JLABS will host the 2021 IDea Incubator, the premier showcase of technology in the field of infectious diseases and a pitch-style competition that drives innovations across various disciplines with the potential to improve the infectious diseases specialty and patient care.

Key Points: 
  • ARLINGTON, Va., June 10, 2021 /PRNewswire-PRWeb/ -- The Infectious Diseases Society of America (IDSA) Foundation, in collaboration with Johnson & Johnson Innovation JLABS will host the 2021 IDea Incubator, the premier showcase of technology in the field of infectious diseases and a pitch-style competition that drives innovations across various disciplines with the potential to improve the infectious diseases specialty and patient care.
  • "The IDea Incubator competition uncovers and highlights groundbreaking solutions that help reduce the burdens of infectious diseases worldwide," said Javeed Siddiqui, MD, MPH, creator of the IDea Incubator and co-founder and chief medical officer of TeleMed2U.
  • Blue Knight residency opportunities may be offered to eligible companies at select JLABS locations, including JLABS @ Washington, DC the hub for Blue Knight.
  • IDWeek is the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS).

Microbix Announces Quality Products Distribution Agreement

Retrieved on: 
Monday, May 31, 2021

MISSISSAUGA, Ontario, May 31, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, announces the appointment of SDT Molecular Pte Ltd (SDT) as distributor of Microbixs quality assessment products (QAPs) for four Asia-Pacific territories.

Key Points: 
  • MISSISSAUGA, Ontario, May 31, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, announces the appointment of SDT Molecular Pte Ltd (SDT) as distributor of Microbixs quality assessment products (QAPs) for four Asia-Pacific territories.
  • SDT brings advanced technologies and innovative products to healthcare professionals, hospitals, and clinical laboratories to improve the lives of patients.
  • Microbixs QAPs line now consists of over 70 products to help support the accuracy of various diagnostic tests for infectious diseases.
  • Phil Casselli, SVP of Sales and Business Development of Microbix stated, SDT approached us looking for products to complete their IVD test offerings.

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine

Retrieved on: 
Thursday, May 27, 2021

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (Excision), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.

Key Points: 
  • SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (Excision), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.
  • We are thrilled to have such an experienced infectious disease clinician join our team as we continue to advance our pipeline of CRISPR-based therapies for viral infectious diseases.
  • In this role, she was the clinical leader across multiple therapeutic areas, in particular infectious diseases, integrating discovery research and translational medicine to accelerate the development of transformational medicines.
  • Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases.

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

Retrieved on: 
Wednesday, May 26, 2021

Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.

Key Points: 
  • Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.
  • With the recent surge of infections in India, AmphoTLC will address the countrys acute liposomal amphotericin B shortage.
  • The approval of AmphoTLC in India follows the conduct of complete due diligence by regulators in India based on the numerous years of development TLC has dedicated as well as its quality performance in the developed markets.
  • TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases.